Abstract 110P
Background
Cancer of unknown primary (CUP) remains a common major challenge, diagnosed by serially excluding known sites of origin. Median survival, excluding rarer favourable subsets, with first-line combination cytotoxics (platinum based) remain poor under 10 months. Less than 10% are amenable to therapies linked to actionable mutations and less than 20% suitable for 2nd line therapies, with few studies beyond first line therapy and no standard of care. CUP may have unique biology in relation to immune system evasion leading to early metastatic spread. We investigated the feasibility of treatment with Pembrolizumab after failure of at least one line of therapy in a prospective phase 2 trial.
Methods
The study was initiated in 2019 to recruit a minimum of 57 CUP patients treated with and progressing after at least one line of chemotherapy with RECIST measurable disease, across 3 UK centres with Pembrolizumab 200 mg IV Q21d until disease progression or intolerance. Significant Covid trial recruitment disruption in this rare population, revised the study design down to a minimum of 31 patients, (after an interim pre-planned futility analysis at 24 patients) which gave a power 0.80 to detect a 2 months PFS improvement.
Results
35 patients consented with 30 patients assessable (Database lock Aug 2023). Median age 60 (range 33–77), 67% female, ECOG 0-1 vs 2: 83/17%. 63% had 1 line of prior chemotherapy, 27% 2 lines, 10% 3 or more lines & 10% prior radiotherapy. Median PFS (first RECIST PD) was 4.0 months (95% CI 3.2-7.5) and Median OS 11.5 months (95% CI 6.5-NR). At 6/12/18/24 & 36 months, the percentage of patients not progressing on trial treatment were 33/23/17/13/13% respectively. 2 patients who had not progressed, stopped treatment due to related AEs, one of whom has maintained stable disease for >36 mths including 9 months after discontinuation. Pembrolizumab was very well tolerated and there were no unexpected adverse events.
Conclusions
Pembrolizumab should be further investigated in CUP with promising activity and sustained disease control in a significant minority of patients beyond 2nd line with overall survival similar to first line CUP studies. Ongoing Clinico-translational research may identify predictive biomarkers.
Clinical trial identification
EudraCT: 2018-001327-39, NCT03752333.
Editorial acknowledgement
We acknowledge the contribution of Dr Michael Grayer from Floating Point Statistics Ltd who provided statistical consultancy services, supporting this conference paper by analysing the interim data as it stood on 30 August 2023, and producing production-quality tables and figures.
Legal entity responsible for the study
Imperial College London.
Funding
This research has been supported by 1) Grant Ref: MISP 55449 from Merck Sharp and Dohme Limited (MSD); 2) CUPFoundation UK; 3) SR was supported by NHS funding to the National Institute for Health and Care Research Biomedical Research Centre at Royal Marsden NHS Foundation Trust and the Institute of Cancer Research.
Disclosure
H.S. Wasan: Financial Interests, Personal, Advisory Board, Advisory Boards and Invited Speaker: Incyte, Pierre Fabre, Servier, Bayer, Roche/Genentech/FM AG, Sirtex Medical Erytech, Celgene, Array BioPharma, Merck KGaA: BMS; Financial Interests, Personal, Steering Committee Member, Trial steering committee and advisory: Zymeworks; Financial Interests, Personal and Institutional, Coordinating PI, Trial PI steering committee and advisory: Sirtex Medical; Financial Interests, Personal, Other, Consultancy for Submission for UK approval (BSI): ONCOSL; Non-Financial Interests, Personal, Advisory Role, Trial steering committee: Pfizer; Non-Financial Interests, Personal, Advisory Role, UK NICE submission: Bayer, Pierre Fabre. S. Rao: Financial Interests, Personal, Advisory Board: Merck Serono, Servier, Seagen, AstraZeneca, Hoopika, Bayer, BeiGene; Financial Interests, Personal, Expert Testimony: Boehringer; Financial Interests, Personal, Invited Speaker: Merck Serono, Servier, Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display